Welcome to our dedicated page for Lifevantage news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage stock.
LifeVantage Corp (LFVN) delivers science-driven health solutions through nutrigenomic research and dietary supplements. This news hub provides investors and stakeholders with essential updates on corporate developments, product innovations, and market positioning in the nutraceutical industry.
Access timely regulatory filings, earnings reports, and press releases alongside analysis of scientific advancements. Our curated collection includes updates on weight management systems, cognitive enhancement products, and dermatological solutions backed by gene expression research.
Key content categories cover financial performance metrics, research partnerships, product launch details, and corporate governance updates. Bookmark this page for streamlined access to verified information supporting informed decisions about LFVN's market activities.
LifeVantage Corporation (Nasdaq: LFVN) announced it will disclose its financial results for the third quarter, ending March 31, 2023, on May 4, 2023, post-market close. A conference call for investors is scheduled for 2:30 p.m. MT (4:30 p.m. ET) on the same day. Interested participants can call (877) 704-4453 for U.S. access or (201) 389-0920 for international callers. A replay will be available two hours after the call until May 11, 2023. The company specializes in nutrigenomics and offers a variety of dietary supplements and wellness products, including the Protandim family and Petandim for pets. For further details, visit their Investor Relations web page.
LifeVantage Corporation (Nasdaq: LFVN) recently launched the innovative Evolve Compensation Plan, celebrating a successful first month across the U.S., Japan, and Australia. This new plan aims to enhance business-building behaviors among Consultants. Key appointments include Michael Allen as President of LifeVantage Japan and Allana Hinks as General Manager of Australia and New Zealand. The TrueScience® Liquid Collagen product, launched in early March 2023, has already seen significant success, increasing monthly skin care revenue by over 300% since its U.S. debut in June 2022. With this positive momentum, LifeVantage is focusing on geographic and product expansion, positioning itself for improved growth and profitability.
LifeVantage Corporation (Nasdaq: LFVN) has announced a $0.03 cash dividend per share, to be paid on March 15, 2023, for stockholders of record as of March 1, 2023. This dividend reflects the company’s commitment to returning value to shareholders while engaging in nutrigenomics research and product development. LifeVantage, a pioneer in the field, offers a range of dietary supplements and wellness products, including its flagship Protandim® line. Forward-looking statements highlight future growth initiatives and the potential variability of dividends, urging investors to consider associated risks.
FAQ
What is the current stock price of Lifevantage (LFVN)?
What is the market cap of Lifevantage (LFVN)?
